Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance - PubMed (original) (raw)
Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance
Yanfeng Chen et al. ISRN Endocrinol. 2011.
Abstract
The present study was carried out to determine the effect of berberine on glucose homeostasis and several biomarkers associated with insulin sensitivity in male Wistar rats with intraperitoneal injection of streptozotocin (STZ)-induced diabetes. Rats with fasting blood glucose 16.7 mmol/L after 2 weeks of STZ injection were divided into two groups. One group was used as the diabetic control and another treated by gavage feeding with 100 mg/kg/d of berberine in water containing 0.5% carboxymethyl cellulose. A group of rats without receiving STZ was used as the normal control. After 7 weeks, berberine supplementation moderately but significantly lowered fasting blood glucose levels and improved oral glucose tolerance. Berberine lowered plasma free fatty acids and C-reactive protein levels without affecting plasma insulin levels. Diabetic rats treated with berberine showed significantly lower plasma triacylglycerol and cholesterol levels. Furthermore, berberine inhibited dipeptidyl peptidase-4 and protein tyrosine phosphatase-1B activities. In conclusion, berberine showed a dramatic effect of lowering blood cholesterol and triacylglycerols and improved moderately glucose homeostasis in STZ-induced diabetic rats in association with multiple factors related to insulin resistance.
Figures
Figure 1
Oral administration of BBR lowered fasting blood glucose levels in streptozotocin-induced diabetic rats. NC: normal control; DB: diabetic control; BBR: diabetic rats gavaged with 100 mg/kg/d of berberine chloride dissolved in 0.5% carboxymethyl cellulose. The DB and NC groups were gavaged with the control vehicle of 0.5% carboxymethyl cellulose. Values are means ± S.E.M. (at week 0, n = 10 for all groups; at week 7, n = 10, 8, and 7 for the NC, DB, and BBR, resp.). a, b, c Mean values with different letters were significantly different (P < 0.05).
Figure 2
BBR treatment improved oral glucose tolerance in streptozotocin-induced diabetic rats. NC: normal control; DB: diabetic control; BBR: diabetic rats gavaged with 100 mg/kg/d of berberine chloride dissolved in 0.5% carboxymethyl cellulose. The DB and NC groups were gavaged with the control vehicle of 0.5% carboxymethyl cellulose. Values are means ± S.E.M. (n = 10, 8, and 7 for the NC, DB, and BBR, resp.). *different from the DB and BBR groups (P < 0.0001), respectively. **different from the DB group (P < 0.05).
Figure 3
Dose response of BBR on DPP-4 (a) and PTP-1B (b) enzyme activities.
Similar articles
- Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.
Xu XH, Hu Q, Zhou LS, Xu LJ, Zou X, Lu FE, Yi P. Xu XH, et al. Curr Med Sci. 2020 Jun;40(3):530-538. doi: 10.1007/s11596-020-2210-4. Epub 2020 Jul 17. Curr Med Sci. 2020. PMID: 32681256 - The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.
Zhang M, Lv XY, Li J, Xu ZG, Chen L. Zhang M, et al. Exp Diabetes Res. 2008;2008:704045. doi: 10.1155/2008/704045. Epub 2009 Jan 4. Exp Diabetes Res. 2008. PMID: 19132099 Free PMC article. - Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion.
Leng SH, Lu FE, Xu LJ. Leng SH, et al. Acta Pharmacol Sin. 2004 Apr;25(4):496-502. Acta Pharmacol Sin. 2004. PMID: 15066220 - Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Jiang SJ, Dong H, Li JB, Xu LJ, Zou X, Wang KF, Lu FE, Yi P. Jiang SJ, et al. World J Gastroenterol. 2015 Jul 7;21(25):7777-85. doi: 10.3748/wjg.v21.i25.7777. World J Gastroenterol. 2015. PMID: 26167077 Free PMC article. - Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Wang Y, et al. Metabolism. 2011 Feb;60(2):298-305. doi: 10.1016/j.metabol.2010.02.005. Epub 2010 Mar 20. Metabolism. 2011. PMID: 20304443
Cited by
- A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects.
Askari VR, Khosravi K, Baradaran Rahimi V, Garzoli S. Askari VR, et al. Pharmaceuticals (Basel). 2023 Dec 20;17(1):7. doi: 10.3390/ph17010007. Pharmaceuticals (Basel). 2023. PMID: 38275993 Free PMC article. Review. - Insights into the Therapeutic uses of Plant Derive Phytocompounds onDiabetic Nephropathy.
Mitra P, Jana S, Roy S. Mitra P, et al. Curr Diabetes Rev. 2024;20(9):e230124225973. doi: 10.2174/0115733998273395231117114600. Curr Diabetes Rev. 2024. PMID: 38265383 Review. - Active natural compounds perturb the melanoma risk-gene network.
Shao L, Zhao Y, Heinrich M, Prieto-Garcia JM, Manzoni C. Shao L, et al. G3 (Bethesda). 2024 Feb 7;14(2):jkad274. doi: 10.1093/g3journal/jkad274. G3 (Bethesda). 2024. PMID: 38035793 Free PMC article. - Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome.
Suman RK, Borde MK, Mohanty IR, Singh HK. Suman RK, et al. Int J Appl Basic Med Res. 2023 Jul-Sep;13(3):133-142. doi: 10.4103/ijabmr.ijabmr_115_23. Epub 2023 Sep 25. Int J Appl Basic Med Res. 2023. PMID: 38023603 Free PMC article. - Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review.
Cortez-Navarrete M, Pérez-Rubio KG, Escobedo-Gutiérrez MJ. Cortez-Navarrete M, et al. Pharmaceuticals (Basel). 2023 Mar 30;16(4):515. doi: 10.3390/ph16040515. Pharmaceuticals (Basel). 2023. PMID: 37111272 Free PMC article. Review.
References
- Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Alternative Medicine Review. 1997;2(2):94–103.
- Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacologica Sinica. 2004;25(4):496–502. - PubMed
- Zhou JY, Zhou SW, Zhang KB, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biological and Pharmaceutical Bulletin. 2008;31(6):1169–1176. - PubMed
- Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism. 2010;60:298–305. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials